Da kun ganske få patienter bliver udsat for ekstravasation af antracykliner, er Savene blevet udpeget som "lægemiddel til sjældne sygdomme" den 19. september 2001.
Because the number of patients who have extravasation due to anthracyclines is low, the condition is rare, and Savene was designated an ‘ orphan medicine’ (a medicine used in rare diseases) on 19 September 2001.